Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3906/sag-2011-32 http://scihub22266oqcxt.onion/10.3906/sag-2011-32 33315349!8219078!33315349     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Turk+J+Med+Sci 2021 ; 51 (2): 448-453 Nephropedia Template TP {{tp|p=33315349|t=2021. The predictive and diagnostic accuracy of long pentraxin-3 in COVID-19 pneumonia |pdf=|usr=}}{{33315349}} gab.com Text The predictive and diagnostic accuracy of long pentraxin-3 in COVID-19 pneumonia JO: Turk J Med Sci http://www.kidney.de/pget.php?&tw=1&pmid=33315349 #FOAvip BACKGROUND/AIM: The purpose of this study is to evaluate serum pentraxin-3 (PTX-3) levels in Sars-CoV-2 virus infection (COVID-19) patients and to investigate whether PTX-3 predicts the disease prognosis. MATERIALS AND METHODS: This study was conducted on 88 confirmed COVID-19 patients who were hospitalized due to symptomatic pneumonia between April 15 and August 15, 2020. The patients were divided into two groups as survived patients and non-survived patients. Both groups were compared according to demographic features, comorbid conditions and measurement of the PTX-3 and other laboratory parameters of the patients. RESULTS: Of 88 patients with COVID-19, 59 (67%) were discharged with complete cure and 29 (33%) resulted in death. 46 (52.3%) of the patients were men. PTX-3 median value (IQR) was 3.66 ng/mL (0.9-27.9) in all patients, 3.3 ng/mL (0.9-27.9) in survivors and 3.91 ng/mL (1.9-23.2) in nonsurvivors which was significantly higher (P = 0.045). As a receiver operating characteristic curve analysis the cut-off value of PTX-3 for predicting mortality in patients was 3.73 with 65% sensitivity and 65% specificity (AUC: 0.646, 95% CI: 0.525- 0.767, P = 0.045). Also, we found significant cut-off values with respect to D-dimer, D-dimer/PTX-3, high-sensitivity troponin, high- sensitivity troponin/PTX-3, lymphocyte, PTX-3/lymphocyte, procalcitonin, procalcitonin/PTX-3, CRP, and CRP/PTX-3 (P < 0.05). CONCLUSION: In this study, as far as we know, for the first time, we have shown PTX-3 as the new mortality biomarker for COVID-19 disease. Twit Text FOAVip The predictive and diagnostic accuracy of long pentraxin-3 in COVID-19 pneumonia ????Turk J Med Sci http://www.kidney.de/pget.php?&tw=1&pmid=33315349 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33315349 #FOAvip English Wikipedia <ref>{{Cite pmid|33315349}}</ref> The predictive and diagnostic accuracy of long pentraxin-3 in COVID-19 pneumonia #MMPMID33315349 Genc AB; Yaylaci S; Dheir H; Genc AC; Issever K; Cekic D; Kocayigit H; Cokluk E; Karacan A; Sekeroglu MR; Toptan Cakar H; Guclu E Turk J Med Sci 2021[Apr]; 51 (2): 448-453 PMID33315349show ga BACKGROUND/AIM: The purpose of this study is to evaluate serum pentraxin-3 (PTX-3) levels in Sars-CoV-2 virus infection (COVID-19) patients and to investigate whether PTX-3 predicts the disease prognosis. MATERIALS AND METHODS: This study was conducted on 88 confirmed COVID-19 patients who were hospitalized due to symptomatic pneumonia between April 15 and August 15, 2020. The patients were divided into two groups as survived patients and non-survived patients. Both groups were compared according to demographic features, comorbid conditions and measurement of the PTX-3 and other laboratory parameters of the patients. RESULTS: Of 88 patients with COVID-19, 59 (67%) were discharged with complete cure and 29 (33%) resulted in death. 46 (52.3%) of the patients were men. PTX-3 median value (IQR) was 3.66 ng/mL (0.9-27.9) in all patients, 3.3 ng/mL (0.9-27.9) in survivors and 3.91 ng/mL (1.9-23.2) in nonsurvivors which was significantly higher (P = 0.045). As a receiver operating characteristic curve analysis the cut-off value of PTX-3 for predicting mortality in patients was 3.73 with 65% sensitivity and 65% specificity (AUC: 0.646, 95% CI: 0.525- 0.767, P = 0.045). Also, we found significant cut-off values with respect to D-dimer, D-dimer/PTX-3, high-sensitivity troponin, high- sensitivity troponin/PTX-3, lymphocyte, PTX-3/lymphocyte, procalcitonin, procalcitonin/PTX-3, CRP, and CRP/PTX-3 (P < 0.05). CONCLUSION: In this study, as far as we know, for the first time, we have shown PTX-3 as the new mortality biomarker for COVID-19 disease. |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Area Under Curve[MESH] |Biomarkers/metabolism[MESH] |C-Reactive Protein/*metabolism[MESH] |COVID-19/*metabolism/mortality[MESH] |Female[MESH] |Fibrin Fibrinogen Degradation Products/metabolism[MESH] |Humans[MESH] |Lymphocyte Count[MESH] |Male[MESH] |Middle Aged[MESH] |Mortality[MESH] |Procalcitonin/metabolism[MESH] |Prognosis[MESH] |ROC Curve[MESH] |SARS-CoV-2[MESH] |Serum Amyloid P-Component/*metabolism[MESH] |Troponin/metabolism[MESH]The predictive and diagnostic accuracy of long pentraxin-3 in COVID-19(epmc).pdf DeepDyve Pubget Overpricing